2019
Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma
Thornton M, Williamson H, Westbrook K, Greenup R, Plichta J, Rosenberger L, Gupta A, Hyslop T, Hwang E, Fayanju O. Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma. Annals Of Surgical Oncology 2019, 26: 3166-3177. PMID: 31342392, PMCID: PMC6736696, DOI: 10.1245/s10434-019-07564-9.Peer-Reviewed Original ResearchConceptsNeoadjuvant endocrine therapyInvasive lobular carcinomaOverall survivalEndocrine therapyLobular carcinomaHormone receptor-positive groupNational Cancer Data BaseLower ratesPathologic complete responseKaplan-Meier curvesReceptor-positive groupCox proportional hazardsBackgroundNeoadjuvant chemotherapyCN1-3More comorbiditiesPostmastectomy radiationNeoadjuvant chemotherapyNeoadjuvant therapyComplete responseClinical trialsBreast cancerCT classificationSmall tumorsProportional hazardsGreater burden
2018
Axillary Nodal Evaluation in Elderly Breast Cancer Patients: Potential Effects on Treatment Decisions and Survival
Tamirisa N, Thomas S, Fayanju O, Greenup R, Rosenberger L, Hyslop T, Hwang E, Plichta J. Axillary Nodal Evaluation in Elderly Breast Cancer Patients: Potential Effects on Treatment Decisions and Survival. Annals Of Surgical Oncology 2018, 25: 2890-2898. PMID: 29968029, PMCID: PMC6404232, DOI: 10.1245/s10434-018-6595-2.Peer-Reviewed Original ResearchConceptsBreast cancer patientsElderly breast cancer patientsCN0 breast cancerOverall survivalNodal surgeryCancer patientsAxillary surgeryElderly patientsTreatment decisionsBreast cancerCharlson-Deyo comorbidity scoreCN0 breast cancer patientsSurgical lymph node evaluationCox proportional hazards modelAdjuvant therapy decisionsAdjuvant therapy receiptAxillary nodal evaluationLymph node evaluationNational Cancer DatabaseYear of diagnosisWorse overall survivalEstrogen receptor statusLong-term outcomesSubsequent treatment decisionsProportional hazards model
2017
Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer
Gamble C, Havrilesky L, Myers E, Chino J, Hollenbeck S, Plichta J, Kelly Marcom P, Shelley Hwang E, Kauff N, Greenup R. Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer. Annals Of Surgical Oncology 2017, 24: 3116-3123. PMID: 28699130, PMCID: PMC5990891, DOI: 10.1245/s10434-017-5995-z.Peer-Reviewed Original ResearchConceptsRisk-reducing mastectomyOvarian cancer diagnosisIncremental cost-effectiveness ratioBRCA mutation carriersMonths of lifeMutation carriersMagnetic resonance imagingCancer diagnosisSurvival benefitOvarian cancerMutation statusMost BRCA1/2 mutation carriersThird-party payer perspectiveGreater survival benefitBreast cancer riskBRCA mutation statusBRCA1/2 mutation carriersBRCA2 mutation carriersBRCA2 mutation statusBRCA1 mutation carriersBreast cancer screeningMonte Carlo probabilistic sensitivity analysisCost-effectiveness ratioYears of lifeProbabilistic sensitivity analyses
2015
Evaluation of Pathologic Nipple Discharge: What is the Added Diagnostic Value of MRI?
Bahl M, Baker J, Greenup R, Ghate S. Evaluation of Pathologic Nipple Discharge: What is the Added Diagnostic Value of MRI? Annals Of Surgical Oncology 2015, 22: 435-441. PMID: 26249144, DOI: 10.1245/s10434-015-4792-9.Peer-Reviewed Original ResearchConceptsPathologic nipple dischargeMagnetic resonance imagingNipple dischargeNegative predictive valuePositive predictive valuePredictive valueDiagnostic valueNegative magnetic resonance imagingSpecificity of MRIBreast magnetic resonance imagingEvaluation of patientsValuable additional diagnostic toolRadiology Breast Imaging ReportingBI-RADS 1Data System 4Detection of malignancyAdditional diagnostic toolBreast Imaging ReportingSonographic workupDuct explorationRetrospective reviewSurgical excisionRadiographic findingsDuctal carcinomaSymptomatic population
2013
Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort
Greenup R, Buchanan A, Lorizio W, Rhoads K, Chan S, Leedom T, King R, McLennan J, Crawford B, Kelly Marcom P, Shelley Hwang E. Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort. Annals Of Surgical Oncology 2013, 20: 3254-3258. PMID: 23975317, DOI: 10.1245/s10434-013-3205-1.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerBRCA mutation prevalenceRace/ethnicityBRCA mutationsGenetic counselingBreast cancerMutation prevalenceGenetic mutationsAfrican AmericansHereditary cancer clinicBRCA mutation statusBRCA genetic mutationPersonalized genetic counselingConclusionsThe prevalenceNCCN guidelinesPrimary outcomeRetrospective reviewTNBC subtypesResultsA totalBRCA2 mutationsCancer clinicMutation statusDemographic dataPrevalenceEthnicity/race
2012
Application of ACOSOG Z0011 Criteria Reduces Perioperative Costs
Camp M, Greenup R, Taghian A, Coopey S, Specht M, Gadd M, Hughes K, Smith B. Application of ACOSOG Z0011 Criteria Reduces Perioperative Costs. Annals Of Surgical Oncology 2012, 20: 836-841. PMID: 23010735, DOI: 10.1245/s10434-012-2664-0.Peer-Reviewed Original ResearchMeSH KeywordsAxillaBreast NeoplasmsCombined Modality TherapyCost-Benefit AnalysisFemaleFollow-Up StudiesHumansLymph Node ExcisionLymphatic MetastasisMastectomy, SegmentalNeoplasm Recurrence, LocalNeoplasm StagingPractice Guidelines as TopicPrognosisRetrospective StudiesSentinel Lymph Node BiopsySurvival RateConceptsAxillary lymph node dissectionCompletion axillary lymph node dissectionPerioperative surgical managementOvernight admissionPerioperative costsZ0011 criteriaSurgical managementBreast cancerSentinel lymph node-positive breast cancerLymph node-positive breast cancerNode-positive breast cancerACOSOG Z0011 criteriaACOSOG Z0011 trialOvernight hospital admissionLymph node dissectionRetrospective chart reviewInvasive breast cancerBreast conservation therapyInpatient hospital daysPositive breast cancerExcellent regional controlPositive SLNZ0011 trialEligible patientsNode dissectionCost Comparison of Radiation Treatment Options After Lumpectomy for Breast Cancer
Greenup R, Camp M, Taghian A, Buckley J, Coopey S, Gadd M, Hughes K, Specht M, Smith B. Cost Comparison of Radiation Treatment Options After Lumpectomy for Breast Cancer. Annals Of Surgical Oncology 2012, 19: 3275-3281. PMID: 22851048, DOI: 10.1245/s10434-012-2546-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBrachytherapyBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingCarcinoma, LobularCombined Modality TherapyCosts and Cost AnalysisFemaleFollow-Up StudiesHealth Care CostsHumansMastectomy, SegmentalMiddle AgedNeoplasm GradingNeoplasm InvasivenessPrognosisRetrospective StudiesConceptsWhole breast radiation therapyBreast cancerRT optionsExternal-beam partial breast irradiationLeukemia Group B 9343MethodsAn institutional review boardResultsMedian patient ageCurrent Procedural Terminology codesMedian tumor sizeInvasive ductal cancerSitu breast cancerPartial breast irradiationProcedural Terminology codesRadiation treatment optionsInstitutional review boardC-RTBackgroundRadiation therapyRT regimensBreast conservationDuctal cancerLobular cancerMixed histologyPatient ageRetrospective reviewTumor histology